ResearchSafe

Mayo grad student's aptamer idea clears senescent cells in mice

Posted by tinkerer184 in Research & News - 1 points, 4 comments.

https://www.sciencedaily.com/releases/2026/05/260515001733.htm

So this one caught my eye because it's a Mayo Clinic story about a grad student just chatting with other grad students and landing on aptamers that stick to zombie cells, the senescent ones that pile up as we age and seem to drive a lot of the inflammation mess. The mice results apparently looked good, which is exciting, but I'm keeping my skeptical hat on because mice aren't people, and senolytics have had a rough road so far with translation. The cool part for me is that aptamers are basically little synthetic DNA or RNA snippets, so in theory they could be tuned more precisely than the small molecule drugs people have been trying, and maybe with fewer off-target issues.

But until I see safety data in humans and understand the mechanism better, I'm filing this under "promising, not proven." Anyone here following the senolytic space closely, and do you think aptamers are actually a meaningful step up from the dasatinib plus quercetin type stuff, or is it just a new wrapper on the same idea?

Comments

  • midwestmel: I have been loosely following the senolytic space and yeah, mice to human translation has been a mess, so I get why you're cautious. Aptamers as a class do seem interesting to me, the specificity angle is real. From a molecular standpoint you can iterate binding way faster than small molecules, and the off-target profile can be tighter in principle. But I keep coming back to the same question, are we even sure the same senescent cell surface markers translate cleanly between a 2-year-old mouse
  • tinkerer184: And that's the exact thing nagging at me too, like if the surface markers shift between species then the aptamer is basically targeting a moving target. I'd love to see a paper comparing senescent cell surface proteomes across species before anyone gets too hyped. Fwiw the grad student angle is what got me reading this in the first place, sometimes the best ideas come from people who aren't locked into the usual drug discovery mindset. What got you into following this space?
  • rational_coldplunge: That cross-species marker question is honestly the thing I'd want answered first too. Mice and humans don't even age on the same timeline, so yeah I'd be surprised if the surface markers were a clean 1:1. To be fair nobody's saying it is, but until that gets nailed down the whole approach feels like building on sand a bit.
  • tinkerer184: Yeah, exactly that. The marker mismatch is what keeps me from getting too hyped, plus the dosing and clearance timeline would obviously be totally different in humans. The aptamer angle is neat tho, because in theory you could swap the target sequence if one marker doesn't pan out, which you can't really do with a small molecule that took years to optimize. I'm gonna keep my eyes on this one but agree, way too early to call it a win 😎

Community discussion - research and educational context only. Not medical advice.